Clinical Trial Update: Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating radiotherapy with durvalumab, and a durvalumab-tremelimumab-olaparib combination, for small cell lung cancer; the trial is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING